Inotek Pharmaceuticals Corp., of Lexington, Mass., said the Journal of Ocular Pharmacology and Therapeutics published results from its phase I dose-escalation trial of lead candidate trabodenoson, showing that doses up to 3,200 mcg per eye were safe and well tolerated, both in the eye and systemically, in healthy adult volunteers.